Pradip Patel, MD
Cardiology · Terre Haute, INNPI 1215912993
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 394 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,448 and has fallen 74.8% since, to $365 in 2025.
Across 394 payments — averaging $16.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- E.r. Squibb & Sons, L.L.C.$678
- AstraZeneca$635
- Boehringer Ingelheim$577
- Novo Nordisk$547
- Novartis$540
- plus $2K from 23 others
What the payments were for
- Food & beverage$6,26899%
- Education$571%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 64 | $1,196 |
| E.r. Squibb & Sons, L.L.C. | 60 | $678 |
| AstraZeneca | 36 | $635 |
| Boehringer Ingelheim | 31 | $577 |
| Novo Nordisk | 29 | $547 |
| Novartis | 32 | $540 |
| Pfizer | 29 | $354 |
| Johnson & Johnson | 28 | $304 |
| Esperion Therapeutics, Inc. | 20 | $298 |
| Sanofi-aventis U.S. LLC | 9 | $263 |
| Kowa Pharmaceuticals America, Inc. | 12 | $184 |
| Bayer | 9 | $151 |
| Merck | 8 | $113 |
| Chiesi USA, Inc. | 4 | $79 |
| Azurity Pharmaceuticals, Inc. | 3 | $55 |
| Arbor Pharmaceuticals, Inc. | 2 | $45 |
| Astellas Pharma US Inc | 2 | $38 |
| Lundbeck LLC | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 2 | $35 |
| GSK | 2 | $27 |
| Gilead | 2 | $25 |
| Angiodynamics, Inc. | 1 | $21 |
| Biotronik Inc. | 1 | $21 |
| Inari Medical, Inc. | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Abbott | 1 | $17 |
| Impulse Dynamics (USA) Inc. | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $14 |
How this compares
Too few cardiology providers in Indianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 197 | $229,879 |
| EliquisApixaban | 156 | $186,271 |
| JardianceEmpagliflozin | 68 | $99,787 |
| OzempicSemaglutide | 82 | $90,657 |
| FarxigaDapagliflozin Propanediol | 14 | $23,581 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $18,964 |
| Ranolazine ErRanolazine | 77 | $17,000 |
| Nebivolol Hcl | 55 | $4,974 |
| Metoprolol Succinate | 155 | $2,823 |
| Atorvastatin Calcium | 236 | $2,218 |
| ClopidogrelClopidogrel Bisulfate | 140 | $2,196 |
| Pantoprazole Sodium | 124 | $1,938 |
| Levothyroxine Sodium | 155 | $1,887 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,844 |
| Famotidine | 98 | $1,686 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $354 | $186,271156 claims |
| Boehringer IngelheimJardiance | $577 | $99,78768 claims |
| Novo NordiskOzempic | $547 | $90,65782 claims |
| AstraZenecaFarxiga | $635 | $23,58114 claims |
| MerckJanumet | $113 | $18,96415 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cardiology providers in Indianaon file to place this against a meaningful peer group, so we don't.
Other cardiology in Terre Haute
- Primo AndresTerre Haute$4K
- Suhail KhadraMunster$5K
- Amanda LyonCarmel$280
- Elizabeth RiddellLafayette$0
- Dennis DickosIndianapolis$0
- Poonam PuranikIndianapolis$0
- Sabena HussainIndianapolis$0
- Timothy CordesIndianapolis$0
- Keith McLeanMadison$0
- Jacqueline MaiersIndianapolis$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.